Allergy Therapeutics (GB:AGY) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Allergy Therapeutics has submitted a Marketing Authorisation Application to Germany’s Paul Ehrlich Institut for its innovative Grass MATA MPL allergy treatment. This submission marks a crucial step in the regulatory process for the subcutaneous immunotherapy designed to alleviate symptoms of grass pollen allergies. The application is supported by comprehensive data, including a pivotal Phase III trial showcasing significant efficacy over placebo.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
